Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Atropine in the Treatment of Myopia Study in Malaysia (ATOM-MY): A Randomized, Double-Blind Study to Demonstrate the Efficacy and Safety of Eye Drop Formulations (Atropine Sulphate 0.025 % w/v Eye Drops vs Placebo) in the Management of Controlling Progression of Myopia in Children.

NCT07329777 is registered in ClinicalTrials.gov with IDB VisionCare SDN BHD as lead sponsor.

NCT NCT07329777
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07329777 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Atropine in the Treatment of Myopia Study in Malaysia (ATOM-MY): A Randomized, Double-Blind Study to Demonstrate the Efficacy and Safety of Eye Drop Formulations (Atropine Sulphate 0.025 % w/v Eye Drops vs Placebo) in the Management of Controlling Progression of Myopia in Children.
Lead sponsor
IDB VisionCare SDN BHD
Phase
Phase 3
Overall status
Recruiting
Start date
September 17, 2025
Completion date
September 30, 2029
Enrollment
144 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

myopia progression